We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bone Metabolism After Laparoscopic Gastric Bypass Surgery (BABS) (BABS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01739855
First Posted: December 4, 2012
Last Update Posted: August 25, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dr. Christian Muschitz, Medical University of Vienna
  Purpose

Bariatric surgery leads to rapid weight loss in female and male patients. Less data are available about its impact on bone metabolism.

The aim of this study is the investigation of changes in bone mineral density,bone histomorphometric changes, serum bone turnover markers and changes in body fat and muscle composition in patients after laparoscopic gastric bypass surgery.


Condition Intervention Phase
Evaluation of Expected Bone Loss After Bariatric Surgery Possible Prevention of Bone Loss After Surgery by Calcium and Vitamin D Supplementation Drug: Calciferol, calcium carbonate Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Patients Undergoing Bariatric Surgery (Laparoscopic Gastric Bypass) and Evaluation of Bone Metabolism With/Without Vitamin D/Calcium Supplementation

Resource links provided by NLM:


Further study details as provided by Dr. Christian Muschitz, Medical University of Vienna:

Primary Outcome Measures:
  • Evaluation of bone mineral density changes in obese patients after laparoscopic bariatric surgery [ Time Frame: Evaluation every 6 months for 24 months ]

    Dual energy X-ray absorptiometry (DXA) measurements of bone mineral density at lumbar spine, hip, calcaneus and total body will be performed at baseline and every six months for a period of 24 months.

    Differences will be evaluated on the outcome with/without daily calcium (500mg) and weekly vitamin D (16.000 IU calciferol) supplementation



Secondary Outcome Measures:
  • Evaluation of changes of serum bone turnover markers in obese patients after laparoscopic bariatric surgery [ Time Frame: Evaluation every 3 months for 24 months ]

    Fasting serum markers of bone formation and bone resorption will be evaluated:

    Calcium, 25-OH-vitamin D3, intact parathyroid hormone, beta-crosslaps, type-1-procollagen, bone specific alkaline phosphatase, osteocalcin, sclerostin, osteoprotegerin, cathepsin-K, fibroblast factor 23, lipoprotein A, dickkopf 1 Differences will be evaluated on the outcome with/without daily calcium (500mg) and weekly vitamin D (16.000 IU calciferol) supplementation



Other Outcome Measures:
  • Evaluation of histomorphometric and histologic changes in obese patients after laparoscopic bariatric surgery [ Time Frame: baseline and after 24 months ]

    Transiliac bone biopsies will be performed in a approximately 15% of patients at baseline and after 24 months.

    The following parameters will be measured: bone volume (BV/TV), bone surface (BS/BV), osteoblast surface (OS/BS), trabecular number (TbN), trabecular thickness (TbTh, trabecular separation (Tb.sp), mineralized surface (MS/BS), mineral apposition rate (MAR) Differences will be evaluated on the outcome with/without daily calcium (500mg) and weekly vitamin D (16.000 IU colecalciferol) supplementation



Enrollment: 160
Study Start Date: November 2012
Study Completion Date: August 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Calcium/Vitamin D

All subjects will receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery as follows:

daily: 500 mg oral calcium (calcium carbonate) weekly: 16.000 IU oral vitamin D3 (calciferol)

Drug: Calciferol, calcium carbonate
No Intervention: No Calcium/Vitamin D
All subjects will not receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery.

Detailed Description:

Obese female and male adult patients eligible for laparoscopic gastric bypass surgery according to the national Austrian guidelines will be included in this study upon request and after patient approval.

Baseline data collection and quarterly follow up visits are planned to investigate the changes in bone mineral density and body composition measured by dual energy X-ray absorptiometry as well as the evaluation of serum bone turnover markers of bone formation and resorption.

After surgery subjects will be randomized into two groups:

Daily oral calcium (500mg) and weekly vitamin D3 supplementation (16.000 IU calciferol)or no supplementation of calcium and calciferol.

A sub-study (approximately 15% of study population) with transiliac bone biopsies will also be performed to investigate histomorphometric and histologic changes in bone (biopsy baseline and after 24 months).

The planned duration of the study is 24 months for each subject. Serum bone turnover markers will be collected every 3 months, dual energy X-ray absorptiometry measurements will be performed every 6 months.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • body mass index >35
  • female and male patients
  • age 18 - 65 years
  • eligible for laparoscopic gastric bypass surgery according to the Austrian national guidelines

Exclusion Criteria:

  • any history of malignancy except basalioma
  • any prior antiresorptive treatment
  • any prior calcium or vitamin D supplementation
  • any secondary disease affecting bone metabolism
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01739855


Locations
Austria
Medical University Vienna
Vienna, Austria, 1060
Sponsors and Collaborators
Medical University of Vienna
Investigators
Principal Investigator: Christian Muschitz, M.D. Medical University Vienna - Austria
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. Christian Muschitz, Senior Consultant for Internal Medicine, Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01739855     History of Changes
Other Study ID Numbers: Vinforce-015
Vinforce 015 ( Other Identifier: Medical University Vienna )
First Submitted: November 23, 2012
First Posted: December 4, 2012
Last Update Posted: August 25, 2014
Last Verified: August 2014

Additional relevant MeSH terms:
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Calcium, Dietary
Calcium Carbonate
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents